We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Same but different

20 June 2014 By Neil Unmack

The U.S. pharma group’s recent $46 bln bid proposal equates to a lowish 30 pct premium over Shire’s value before speculation intensified this week. Likely synergies and possible rival offers justify Shire’s rebuttal. But the target can’t be complacent about investor support.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)